CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 20 enrolled
Drug / intervention
T89 Group A +5 moredrug
Likely dose
T89 Group A 150mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01679028
NCT01679028Phase 1Completed
CompareCT.gov

Single- and Multiple- Dose-Escalation Study to Investigate the Safety and Tolerability of T89 in Japanese Healthy Volunteers

Tasly Pharmaceuticals, Inc.·interventional·Posted Sep 5, 2012·Updated Nov 24, 2014

In Brief

A Phase 1 clinical trial evaluating T89 Group A, Placebo Group A, and 4 other interventions for Healthy. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of this study is to see how safe an investigational new drug (T89) is and how well healthy Japanese subjects tolerate it when given two single doses and a multiple dose.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsParexel

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 5, 2012
Enrollment StartAug 1, 2012
Primary CompletionOct 1, 2012
Study CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 13.8 years ago

Interventions

T89 Group Adrug

150mg single dose on day 1

Placebo Group Adrug

150mg single dose

Placebo Group Bdrug

300mg single dose

T89 Group Bdrug

300mg single dose

Placebo Group Cdrug

225mg bid

T89 Group Cdrug

225mg bid